Printer Friendly

AGOURON PHARMACEUTICALS REPORTS PRECLINICAL ACTIVITY OF NEW ANTI-TUMOR COMPOUND

 AGOURON PHARMACEUTICALS REPORTS PRECLINICAL ACTIVITY
 OF NEW ANTI-TUMOR COMPOUND
 SAN DIEGO, May 22 /PRNewswire/ -- Agouron Pharmaceuticals Inc. (NASDAQ-NMS: AGPH) today reported that its compound AG-337 has demonstrated significant curative activity in test animals against both intramuscular and intraperitoneal tumors at doses which produced no apparent toxicity.
 The company also confirmed today that the Cancer Research Campaign, a non-profit organization in England, has agreed to sponsor a Phase I clinical trial of AG-337 at the University of Newcastle-Upon-Tyne currently scheduled to begin in the fall of 1992.
 Speaking before the national meeting of the American Association of Cancer Research, Dr. Robert C. Jackson, Agouron's vice president of research and development, described preclinical anti-tumor activity of the drug designated AG-337, a small synthetic compound that inactivates an enzyme which is required for the rapid proliferation of cancer cells. He also said that this compound proved orally active in test animals.
 AG-337 is the second new anti-tumor drug to be described by Agouron scientists to the cancer research community in the past two months. At a European meeting of cancer research scientists held in March 1992, Agouron scientists reported preclinical anti-tumor activity of another compound, designated AG-331, which the company is preparing to bring to clinical trial in the United States. AG-331 and AG-337 both target the enzyme known as thymidylate synthase, but are chemically unrelated to each other and display different pharmacological properties.
 Agouron Pharmaceuticals Inc. is a pioneer and leader in a new technology for the rational design of novel synthetic drugs based upon the molecular structures of proteins which play key roles in human disease. Agouron is currently applying this technology to the design and development of drugs for treatment of cancer, AIDS and other serious diseases.
 -0- 5/22/92
 /CONTACT: Peter Johnson, president and CEO, or Donna Nichols, of Agouron Pharmaceuticals, 619-622-3000/
 (AGPH) CO: Agouron Pharmaceuticals Inc. ST: California IN: MTC SU:


DM-EH -- SD001 -- 3243 05/22/92 11:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 22, 1992
Words:323
Previous Article:PUGET POWER ANNOUNCES REDEMPTION OF 8 7/8 PERCENT BONDS
Next Article:PATRICK PETROLEUM COMPANY INCREASES OWNERSHIP IN MARCUM NATURAL GAS SERVICES, INC.
Topics:


Related Articles
AGOURON SCIENTISTS REPORT RATIONAL DESIGN OF NEW ANTI-TUMOR DRUG
AGOURON PHARMACEUTICALS REPORTS FISCAL 1992 FINANCIAL RESULTS
AGOURON PHARMACEUTICALS ANNOUNCES START OF HUMAN CLINICAL TRIALS FOR NEW ANTI-TUMOR AGENT
AGOURON SUSPENDS DEVELOPMENT OF PSORIASIS AGENT
AGOURON PHARMACEUTICALS REPORTS FISCAL 1993 FINANCIAL RESULTS
AGOURON REPORTS NOVEL ANTI-HIV COMPOUNDS
AGOURON PHARMACEUTICALS TO PRESENT AT HAMBRECHT & QUIST HEALTH CARE CONFERENCE; AGOURON PHARMACEUTICALS REPORTS R&D PROGRESS
AGOURON AND ROCHE TO COLLABORATE ON CANCER DRUGS
Phase I Data Presented on Agouron's Oral Anti-Angiogenesis Drug AG3340 in Patients With Advanced Cancer
Agouron Files Registration Statement for Oncology Divisional Stock

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters